AstraZeneca is a science-driven international biopharmaceutical company focused on research, development and commercialization of prescription drugs, primarily for the treatment of diseases in three major therapeutic areas: Oncology, Cardiovascular, Kidney and Metabolic ( CVRM), and Respiratory diseases & Immunology
Richard Carayan, Regional Medical Manager :
Membership of the PreciDIAB club was motivated by the idea of joining a group of researchers and opinion leaders in an area in which, with our iSGLT2, we hope to contribute to the advancement of knowledge. We are also particularly interested in patient cohorts in renal cardiovascular and metabolic pathologies.
Bayer is an international Life Sciences group, whose core businesses are health and agriculture. Bayer’s products and services are designed to meet the challenges of a growing and aging global population, protecting everyone every day. Creating value through innovation and science, Bayer is strongly committed to sustainable development and adopts transparent and responsible conduct in its activities. In 2020, Bayer had nearly 100,000 employees and generated sales of 41.4 billion euros. The Group spent 4.9 billion euros on R&D.
Bayer’s Pharmaceuticals Division provides healthcare professionals and patients with prescription drugs for the therapeutic areas of cardiology, oncology, women’s health, hematology and ophthalmology as well as radiology. By enabling the diagnosis and treatment of diseases, as well as the development of digital solutions to optimize the patient’s care path, Bayer is working for greater well-being and an improvement in the quality of life of patients.
Mouna Champain, Medical Director France :
Bayer, as a recognized player in the care of patients with cardiovascular pathologies, aims to contribute more widely to improving the care of patients at risk of developing complications, particularly in the context of of their diabetes. The Précidiab Initiative fits perfectly into the positioning we must have to support the molecules in our pipeline through large-scale partnerships!
Defymed is a company developing innovative implantable medical devices. ExOlin® allows the intraperitoneal delivery of insulin by being coupled to an external insulin pump (start of clinical trials expected by the end of 2020). MailPan® is a device for the macro-encapsulation of insulin-secreting cells. Our goal is to find the best device / cell combination in order to hope for the start of clinical trials in 2022.
Dr Manuel PIRES , Defymed Business Developer :
PreciDIAB is a unique opportunity for Defymed to join a network of opinion leaders in the field of diabetes. Through PreciDIAB, Defymed will participate in workshops and strategic discussions with potential partners.
Enterome is a world leader in the discovery and development of new pharmaceuticals derived from the gut microbiota in the fields of cancer, autoimmune, inflammatory and metabolic diseases.
Christophe BONNY , Chief Scientific Officer d’Enterome :
Joining the PreciDIAB initiative Club allows us to integrate the expertise of opinion leaders in metabolic diseases and in particular in the field of Diabetes, to have access to the results of translational studies of cohorts of patients in these pathologies and to have the opportunity to propose and participate in collaborative projects.
Entérosys specializes in high-quality preclinical evaluation services and is developing its own R&D projects in the field of diseases that alter communication between the intestine and the brain through the development of new therapeutic molecules, in particular for the treatment of diabetes. type II and fatty liver disease. The Entérosys company is particularly interested in the enteric nervous system, considered to be an innovative target for treating these pathologies.
Anne Abot, Entérosys CSO :
We joined the PreciDIAB Initiative to contribute to the research effort on diabetes and its co-morbidities, to interact with academic, private and clinical partners to identify new relevant partnerships.
GDBiotech is a spin-off of the Genes Diffusion group which hosts a portfolio of technologies and patents finding applications in fields as varied as molecular diagnostic (qPCR) and immunological (multiplex ELISA) solutions, bioinformatics tools for the automation of DNA sequence analyzes, and the study of the microbiota.
Claude Grenier, CEO of GD Biotech :
Our company has no direct link with human health research. However, we have developed or applied for our activity many technological and even scientific methods similar to those applicable in human health research. We would like to share with the members of this network around these favorite subjects.
Novo Nordisk is an international pharmaceutical company headquartered in Copenhagen, Denmark. We specialize in the treatment of diabetes and other serious chronic diseases such as obesity, rare bleeding diseases and growth disorders.
We employ more than 45,000 people in 80 subsidiaries around the world. Our healthcare solutions are available in 169 countries.
Jean-Paul Roudière, Director of Hospital Relations :
Joining the PreciDIAB initiative club means participating in excellent research on diabetes, but also collaborating with public and private institutional partners in prevention and health promotion programs.
Valbiotis is a Research & Development company committed to scientific innovation, for the prevention and the fight against metabolic diseases in response to unmet medical needs.
Sébastien Peltier, CEO of Valbiotis :
The PreciDIAB club brings together a national network of academic and industrial partners who have skills and expertise in the field of diabetes, it is obvious for Valbiotis to join it and to contribute to scientific excellence.